Grifols


GRIFOLS’ PLASMA WORTH A SHOT (BUY; 27% UPSIDE)

17/09/20 -"Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma marketplace. While the FDA approval for the ..."

Pages
54
Language
English
Published on
17/09/20
You may also be interested by these reports :
14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...

14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...

09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...

01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO